» Articles » PMID: 35280829

Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Mar 14
PMID 35280829
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adult T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous malignant tumor with poor prognosis. However, accurate prognostic stratification factors are still unclear.

Methods: Data from 90 adult T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) patients were collected. The association of gene mutations detected by next-generation sequencing and clinical characteristics with the outcomes of T-ALL/LBL patients were retrospectively analyzed to build three novel risk stratification models through Cox proportional hazards model.

Results: Forty-seven mutated genes were identified. Here, 73.3% of patients had at least one mutation, and 36.7% had ≥3 mutations. The genes with higher mutation frequency were , , and . The most frequently altered signaling pathways were NOTCH pathway, transcriptional regulation pathway, and DNA methylation pathway. Age (45 years old), platelet (PLT) (50 G/L), actate dehydrogenase (LDH) (600 U/L), response in D19-BMR detection, TP53 and cell cycle signaling pathway alterations, and hematopoietic stem cell transplantation (HSCT) were integrated into a risk stratification model of event-free survival (EFS). Age (45 years old), white blood cell (WBC) count (30 G/L), response in D19-BMR detection, TP53 and cell cycle signaling pathway alterations, and HSCT were integrated into a risk stratification model of overall survival (OS). According to our risk stratification models, the 1-year EFS and OS rates in the low-risk group were significantly higher than those in the high-risk group.

Conclusions: Our risk stratification models exhibited good prognostic roles in adult T-ALL/LBL patients and might guide individualized treatment and ultimately improve their outcomes.

Citing Articles

Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1.

Zhang K, Lu J, Fang F, Zhang Y, Yu J, Tao Y J Immunol Res. 2023; 2023:3804605.

PMID: 37767202 PMC: 10522422. DOI: 10.1155/2023/3804605.


Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.

Huang Y, Wan C, Dai H, Xue S Ann Hematol. 2023; 102(8):2001-2013.

PMID: 37227492 DOI: 10.1007/s00277-023-05286-3.

References
1.
Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M . Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021; 96(5):589-598. DOI: 10.1002/ajh.26144. View

2.
Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

3.
Yu C, Chang W, Jou S, Lin T, Chang Y, Lin C . TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci. 2019; 111(1):229-238. PMC: 6942420. DOI: 10.1111/cas.14238. View

4.
Wenzinger C, Williams E, Gru A . Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Curr Hematol Malig Rep. 2018; 13(4):275-288. DOI: 10.1007/s11899-018-0456-8. View

5.
Baldus C, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M . Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica. 2009; 94(10):1383-90. PMC: 2754954. DOI: 10.3324/haematol.2008.005272. View